Cyclerion Readies For Readouts In Sickle Cell, Other Rare, Serious Diseases This Year
Executive Summary
Spun out from Ironwood with a $175m financing, Cyclerion added Bayer and Shire veteran Andreas Busch to its management team as Chief Innovation Officer as it awaits a trio of Phase II data readouts coming this year for its sGC stimulators.
You may also be interested in...
Finance Watch: ADARx Raises $200m, Alltrna Garners $109m To Fund RNA Medicines
Private Company Edition: Recent venture capital mega-rounds of $100m or more include ADARx and Alltrna, which closed five days after CG Oncology brought in $105m. Also, Tisento launched with assets from Cyclerion and $81m in series A funding and Georgiamune raised a $75m series A round.
Finance Watch: With Limited Fundraising Options, Biotechs Restructure To Extend Cash Runways
Mereo will reduce its headcount by 40% to focus on its lead programs while NeuBase revealed a 60% workforce reduction to extend its cash runway. Also, Invivyd (formerly Adagio), Greenlight and BioMarin announced job cuts, while Otonomy and others planned strategic shifts.
Cyclerion Looking To Partner Praliciguat Despite Phase II Fail In Diabetic Nephropathy
The Ironwood spinout thinks its sGC stimulator demonstrated benefit in reducing urine albumin levels in DN patients; notes data improve markedly if one outlier trial site is excluded.